Randomized Phase II Trial Comparing Carboplatin Plus Weekly Paclitaxel and Docetaxel Alone in Elderly Patients With Advanced Non-Small Cell Lung Cancer: North Japan Lung Cancer Group Trial 0801
Makoto Maemondo(Miyagi Prefectural Hospital Organization), Toshihiro Nukiwa(Tohoku University), Naoto Morikawa(Tohoku University), Koji Miwa, Akira Inoue(Tohoku University Hospital), Tomohiro Sakakibara(Tohoku University Hospital), Toshiyuki Harada(Hokkaido hospital), Mariko Kambe(Chubu University), Kenji Ube(Iwate Prefectural Central Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Kazuhiro Usui(Hokkaido University Hospital), Yuji Minegishi, Osamu Ishimoto(Sendai Kousei Hospital), Kana Watanabe(Miyagi Prefectural Hospital Organization), Akihiko Gemma(Nippon Medical School)
Cited by 21
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953